Search

Your search keyword '"Cirkel, Geert A."' showing total 164 results
Start Over Author "Cirkel, Geert A."
164 results on '"Cirkel, Geert A."'

1. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

Author

Smabers, Lidwien P., Wensink, Emerens, Verissimo, Carla S., Koedoot, Esmee, Pitsa, Katerina-Chara, Huismans, Maarten A., Higuera Barón, Celia, Doorn, Mayke, Valkenburg-van Iersel, Liselot B., Cirkel, Geert A., Brousali, Anneta, Overmeer, René, Koopman, Miriam, Braat, Manon N., Penning de Vries, Bas, Elias, Sjoerd G., Vries, Robert G., Kranenburg, Onno, Boj, Sylvia F., and Roodhart, Jeanine M.

Published
2024
Full Text
View/download PDF

2. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis

Author

Schouten, Thijs J., van Goor, Iris W. J. M., Dorland, Galina A., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Brosens, Lodewijk A. A., Busch, Olivier R., Cirkel, Geert A., van Dam, Ronald M., Festen, Sebastiaan, Groot Koerkamp, Bas, van der Harst, Erwin, de Hingh, Ignace H. J. T., Intven, Martijn P. W., Kazemier, Geert, Liem, Mike S. L., van Lienden, Krijn P., Los, Maartje, de Meijer, Vincent E., Patijn, Gijs A., Schreinemakers, Jennifer M. J., Stommel, Martijn W. J., van Tienhoven, Geert Jan, Verdonk, Robert C., Verkooijen, Helena M., van Santvoort, Hjalmar C., Molenaar, I. Quintus, and Daamen, Lois A.

Published
2024
Full Text
View/download PDF

3. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study

Author

Seelen, Leonard W.F., Doppenberg, Deesje, Stoop, Thomas F., Nagelhout, Anne, Brada, Lilly J.H., Bosscha, Koop, Busch, Olivier R., Cirkel, Geert A., den Dulk, Marcel, Daams, Freek, van Dieren, Susan, van Eijck, Casper H.J., Festen, Sebastiaan, Groot Koerkamp, Bas, Haj Mohammad, Nadia, de Hingh, Ignace H.J.T., Lips, Daan J., Los, Maartje, de Meijer, Vincent E., Patijn, Gijs A., Polée, Marco B., Stommel, Martijn W.J., Walma, Marieke S., de Wilde, Roeland F., Wilmink, Johanna W., Molenaar, I. Quintus, van Santvoort, Hjalmar C., and Besselink, Marc G.

Published
2024
Full Text
View/download PDF

5. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort

Author

Taïeb, Julien, Sayah, Lina, Heinrich, Kathrin, Kunzmann, Volker, Boileve, Alice, Cirkel, Geert, Lonardi, Sara, Chibaudel, Benoist, Turpin, Anthony, Beller, Tamar, Hautefeuille, Vincent, Vivaldi, Caterina, Mazard, Thibault, Bauguion, Lucile, Niger, Monica, Prager, Gerald W., Coutzac, Clelia, Benedikt Westphalen, C., Auclin, Edouard, and Pilla, Lorenzo

Published
2023
Full Text
View/download PDF

6. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study

Author

van Goor, Iris W.J.M., Schouten, Thijs J., Verburg, Daphne N., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Brosens, Lodewijk A.A., Busch, Olivier R., Cirkel, Geert A., van Dam, Ronald M., Festen, Sebastiaan, Koerkamp, Bas Groot, van der Harst, Erwin, de Hingh, Ignace H.J.T., Intven, Martijn P.W., Kazemier, Geert, Los, Maartje, Meijer, Gert J., de Meijer, Vincent E., Nieuwenhuijs, Vincent B., Roos, Daphne, Schreinemakers, Jennifer M.J., Stommel, Martijn W.J., Verdonk, Robert C., van Santvoort, Hjalmar C., Daamen, Lois A., and Molenaar, I. Quintus

Published
2024
Full Text
View/download PDF

7. Short- and Long-Term Outcomes of Pancreatic Cancer Resection in Elderly Patients: A Nationwide Analysis

Author

Henry, Anne Claire, Schouten, Thijs J., Daamen, Lois A., Walma, Marieke S., Noordzij, Peter, Cirkel, Geert A., Los, Maartje, Besselink, Marc G., Busch, Olivier R., Bonsing, Bert A., Bosscha, Koop, van Dam, Ronald M., Festen, Sebastiaan, Groot Koerkamp, Bas, van der Harst, Erwin, de Hingh, Ignace H. J. T., Kazemier, Geert, Liem, Mike S., de Meijer, Vincent E., Nieuwenhuijs, Vincent B., Roos, Daphne, Schreinemakers, Jennifer M. J., Stommel, Martijn W. J., Molenaar, I. Quintus, and van Santvoort, Hjalmar C.

Published
2022
Full Text
View/download PDF

8. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients with Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study

Author

Seelen, Leonard W.F., Doppenberg, Deesje, Stoop, Thomas F., Nagelhout, Anne, Brada, Lilly J.H., Bosscha, Koop, Busch, Olivier R., Cirkel, Geert A., den Dulk, Marcel, Daams, Freek, van Dieren, Susan, van Eijck, Casper H.J., Festen, Sebastiaan, Groot Koerkamp, Bas, Haj Mohammad, Nadia, de Hingh, Ignace H.J.T., Lips, Daan J., Los, Maartje, de Meijer, Vincent E., Patijn, Gijs A., Polée, Marco B., Stommel, Martijn W.J., Walma, Marieke S., de Wilde, Roeland F., Wilmink, Johanna W., Molenaar, I. Quintus, van Santvoort, Hjalmar C., and Besselink, Marc G.

Published
2023
Full Text
View/download PDF

9. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma.

Author

Andel, Paul C. M., van Goor, Iris W. J. M., Augustinus, Simone, Berrevoet, Frederik, Besselink, Marc G., Bhojwani, Rajesh, Boggi, Ugo, Bouwense, Stefan A. W., Cirkel, Geert A., van Dam, Jacob L., Djanani, Angela, Dorcaratto, Dimitri, Dreyer, Stephan, den Dulk, Marcel, Frigerio, Isabella, Ghorbani, Poya, Goetz, Mara R., Groot Koerkamp, Bas, Gryspeerdt, Filip, and Hidalgo Salinas, Camila

Published
2025
Full Text
View/download PDF

10. Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma

Author

Daamen, Lois A., Dorland, Galina, Brada, Lilly J.H., Groot, Vincent P., van Oosten, A. Floortje, Besselink, Marc G., Bosscha, Koop, Bonsing, Bert A., Busch, Olivier R., Cirkel, Geert A., van Dam, Ronald M., Festen, Sebastiaan, Groot Koerkamp, Bas, Haj Mohammad, Nadia, van der Harst, Erwin, de Hingh, Ignace H.J.T., Intven, Martijn P.W., Kazemier, Geert, Los, Maartje, de Meijer, Vincent E., Nieuwenhuijs, Vincent B., Roos, Daphne, Schreinemakers, Jennifer M.J., Stommel, Martijn W.J., Verdonk, Robert C., Verkooijen, Helena M., Molenaar, I. Quintus, and van Santvoort, Hjalmar C.

Published
2022
Full Text
View/download PDF

11. Evaluation of the Khorana, PROTECHT, and 5‐SNP scores for prediction of venous thromboembolism in patients with cancer

Author

Guman, Noori A.M., van Geffen, Roos J., Mulder, Frits I., van Haaps, Thijs F., Hovsepjan, Vahram, Labots, Mariette, Cirkel, Geert A., de Vos, Filip Y.F.L., Ten Tije, Albert J., Beerepoot, Laurens V., Tjan‐Heijnen, Vivianne C.G., van Laarhoven, Hanneke W.M., Hamberg, Paul, Vulink, Annelie J.E., Los, Maartje, Zwinderman, Aeilko H., Ferwerda, Bart, Lolkema, Martijn P.J.K., Steeghs, Neeltje, Büller, Harry R., Kamphuisen, Pieter W., and van Es, Nick

Published
2021
Full Text
View/download PDF

12. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis

Author

MS CGO, Cancer, Onderzoek Radiotherapie, Pathologie Pathologen staf, MS Medische Oncologie, MS Radiotherapie, Trialbureau Beeld, MS HOD, Schouten, Thijs J, van Goor, Iris W J M, Dorland, Galina A, Besselink, Marc G, Bonsing, Bert A, Bosscha, Koop, Brosens, Lodewijk A A, Busch, Olivier R, Cirkel, Geert A, van Dam, Ronald M, Festen, Sebastiaan, Groot Koerkamp, Bas, van der Harst, Erwin, de Hingh, Ignace H J T, Intven, Martijn P W, Kazemier, Geert, Liem, Mike S L, van Lienden, Krijn P, Los, Maartje, de Meijer, Vincent E, Patijn, Gijs A, Schreinemakers, Jennifer M J, Stommel, Martijn W J, van Tienhoven, Geert Jan, Verdonk, Robert C, Verkooijen, Helena M, van Santvoort, Hjalmar C, Molenaar, I Quintus, Daamen, Lois A, Dutch Pancreatic Cancer Group, MS CGO, Cancer, Onderzoek Radiotherapie, Pathologie Pathologen staf, MS Medische Oncologie, MS Radiotherapie, Trialbureau Beeld, MS HOD, Schouten, Thijs J, van Goor, Iris W J M, Dorland, Galina A, Besselink, Marc G, Bonsing, Bert A, Bosscha, Koop, Brosens, Lodewijk A A, Busch, Olivier R, Cirkel, Geert A, van Dam, Ronald M, Festen, Sebastiaan, Groot Koerkamp, Bas, van der Harst, Erwin, de Hingh, Ignace H J T, Intven, Martijn P W, Kazemier, Geert, Liem, Mike S L, van Lienden, Krijn P, Los, Maartje, de Meijer, Vincent E, Patijn, Gijs A, Schreinemakers, Jennifer M J, Stommel, Martijn W J, van Tienhoven, Geert Jan, Verdonk, Robert C, Verkooijen, Helena M, van Santvoort, Hjalmar C, Molenaar, I Quintus, Daamen, Lois A, and Dutch Pancreatic Cancer Group

Published
2024

13. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

Author

Onderzoek Medische Oncologie, Cancer, Unit Opleiding Aios, CMM Groep Snippert, MS Hematologie, MS Medische Oncologie, MS CGO, CMM Groep Bos, MS Radiologie, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Hubrecht Institute with UMC, Smabers, Lidwien P, Wensink, Emerens, Verissimo, Carla S, Koedoot, Esmee, Pitsa, Katerina-Chara, Huismans, Maarten A, Higuera Barón, Celia, Doorn, Mayke, Valkenburg-van Iersel, Liselot B, Cirkel, Geert A, Brousali, Anneta, Overmeer, René, Koopman, Miriam, Braat, Manon N, Penning de Vries, Bas, Elias, Sjoerd G, Vries, Robert G, Kranenburg, Onno, Boj, Sylvia F, Roodhart, Jeanine M, Onderzoek Medische Oncologie, Cancer, Unit Opleiding Aios, CMM Groep Snippert, MS Hematologie, MS Medische Oncologie, MS CGO, CMM Groep Bos, MS Radiologie, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Hubrecht Institute with UMC, Smabers, Lidwien P, Wensink, Emerens, Verissimo, Carla S, Koedoot, Esmee, Pitsa, Katerina-Chara, Huismans, Maarten A, Higuera Barón, Celia, Doorn, Mayke, Valkenburg-van Iersel, Liselot B, Cirkel, Geert A, Brousali, Anneta, Overmeer, René, Koopman, Miriam, Braat, Manon N, Penning de Vries, Bas, Elias, Sjoerd G, Vries, Robert G, Kranenburg, Onno, Boj, Sylvia F, and Roodhart, Jeanine M

Published
2024

14. Predicting Long-term Disease-free Survival after Resection of Pancreatic Ductal Adenocarcinoma:A Nationwide Cohort Study

Author

Van Goor, Iris W.J.M., Schouten, Thijs J., Verburg, Daphne N., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Brosens, Lodewijk A.A., Busch, Olivier R., Cirkel, Geert A., Van Dam, Ronald M., Festen, Sebastiaan, Koerkamp, Bas Groot, Van Der Harst, Erwin, De Hingh, Ignace H.J.T., Intven, Martijn P.W., Kazemier, Geert, Los, Maartje, Meijer, Gert J., De Meijer, Vincent E., Nieuwenhuijs, Vincent B., Roos, Daphne, Schreinemakers, Jennifer M.J., Stommel, Martijn W.J., Verdonk, Robert C., Van Santvoort, Hjalmar C., Daamen, Lois A., Molenaar, I. Quintus, Van Goor, Iris W.J.M., Schouten, Thijs J., Verburg, Daphne N., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Brosens, Lodewijk A.A., Busch, Olivier R., Cirkel, Geert A., Van Dam, Ronald M., Festen, Sebastiaan, Koerkamp, Bas Groot, Van Der Harst, Erwin, De Hingh, Ignace H.J.T., Intven, Martijn P.W., Kazemier, Geert, Los, Maartje, Meijer, Gert J., De Meijer, Vincent E., Nieuwenhuijs, Vincent B., Roos, Daphne, Schreinemakers, Jennifer M.J., Stommel, Martijn W.J., Verdonk, Robert C., Van Santvoort, Hjalmar C., Daamen, Lois A., and Molenaar, I. Quintus

Abstract

Objective: To develop a prediction model for long-term (≥5 years) disease-free survival (DFS) after the resection of pancreatic ductal adenocarcinoma (PDAC). Background: Despite high recurrence rates, 10% of patients have long-term DFS after PDAC resection. A model to predict long-term DFS may aid individualized prognostication and shared decision-making. Methods: This nationwide cohort study included all consecutive patients who underwent PDAC resection in the Netherlands (2014-2016). The best-performing prognostic model was selected by Cox-proportional hazard analysis and Akaike's Information Criterion, presented by hazard ratios (HRs) with 95% confidence intervals (CIs). Internal validation was performed, and discrimination and calibration indices were assessed. Results: In all, 836 patients with a median follow-up of 67 months (interquartile range 51-79) were analyzed. Long-term DFS was seen in 118 patients (14%). Factors predictive of long-term DFS were low preoperative carbohydrate antigen 19-9 (logarithmic; HR 1.21; 95% CI 1.10-1.32), no vascular resection (HR 1.33; 95% CI 1.12-1.58), T1 or T2 tumor stage (HR 1.52; 95% CI 1.14-2.04, and HR 1.17; 95% CI 0.98-1.39, respectively), well/moderate tumor differentiation (HR 1.44; 95% CI 1.22-1.68), absence of perineural and lymphovascular invasion (HR 1.42; 95% CI 1.11-1.81 and HR 1.14; 95% CI 0.96-1.36, respectively), N0 or N1 nodal status (HR 1.92; 95% CI 1.54-2.40, and HR 1.33; 95% CI 1.11-1.60, respectively), R0 resection margin status (HR 1.25; 95% CI 1.07-1.46), no major complications (HR 1.14; 95% CI 0.97-1.35) and adjuvant chemotherapy (HR 1.74; 95% CI 1.47-2.06). Moderate performance (concordance index 0.68) with adequate calibration (slope 0.99) was achieved. Conclusions: The developed prediction model, readily available at www.pancreascalculator.com, can be used to estimate the probability of long-term D

Published
2024

15. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection:A Nationwide Analysis

Author

Schouten, Thijs J., van Goor, Iris W.J.M., Dorland, Galina A., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Brosens, Lodewijk A.A., Busch, Olivier R., Cirkel, Geert A., van Dam, Ronald M., Festen, Sebastiaan, Groot Koerkamp, Bas, van der Harst, Erwin, de Hingh, Ignace H.J.T., Intven, Martijn P.W., Kazemier, Geert, Liem, Mike S.L., van Lienden, Krijn P., Los, Maartje, de Meijer, Vincent E., Patijn, Gijs A., Schreinemakers, Jennifer M.J., Stommel, Martijn W.J., van Tienhoven, Geert Jan, Verdonk, Robert C., Verkooijen, Helena M., van Santvoort, Hjalmar C., Molenaar, I. Quintus, Daamen, Lois A., Schouten, Thijs J., van Goor, Iris W.J.M., Dorland, Galina A., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Brosens, Lodewijk A.A., Busch, Olivier R., Cirkel, Geert A., van Dam, Ronald M., Festen, Sebastiaan, Groot Koerkamp, Bas, van der Harst, Erwin, de Hingh, Ignace H.J.T., Intven, Martijn P.W., Kazemier, Geert, Liem, Mike S.L., van Lienden, Krijn P., Los, Maartje, de Meijer, Vincent E., Patijn, Gijs A., Schreinemakers, Jennifer M.J., Stommel, Martijn W.J., van Tienhoven, Geert Jan, Verdonk, Robert C., Verkooijen, Helena M., van Santvoort, Hjalmar C., Molenaar, I. Quintus, and Daamen, Lois A.

Abstract

Background: Novel definitions suggest that resectability status for pancreatic ductal adenocarcinoma (PDAC) should be assessed beyond anatomical criteria, considering both biological and conditional factors. This has, however, yet to be validated on a nationwide scale. This study evaluated the prognostic value of biological and conditional factors for staging of patients with resectable PDAC. Patients and Methods: A nationwide observational cohort study was performed, including all consecutive patients who underwent upfront resection of National Comprehensive Cancer Network resectable PDAC in the Netherlands (2014–2019) with complete information on preoperative carbohydrate antigen (CA) 19-9 and Eastern Cooperative Oncology Group (ECOG) performance status. PDAC was considered biologically unfavorable (RB+) if CA19-9 ≥ 500 U/mL and favorable (RB−) otherwise. ECOG ≥ 2 was considered conditionally unfavorable (RC+) and favorable otherwise (RC−). Overall survival (OS) was assessed using Kaplan–Meier and Cox-proportional hazard analysis, presented as hazard ratios (HRs) with 95% confidence interval (CI). Results: Overall, 688 patients were analyzed with a median overall survival (OS) of 20 months (95% CI 19–23). OS was 14 months (95% CI 10 months—median not reached) in 20 RB+C+ patients (3%; HR 1.61, 95% CI 0.86–2.70), 13 months (95% CI 11–15) in 156 RB+C− patients (23%; HR 1.86, 95% CI 1.50–2.31), and 21 months (95% CI 12–41) in 47 RB−C+ patients (7%; HR 1.14, 95% CI 0.80–1.62) compared with 24 months (95% CI 22–27) in 465 patients with RB−C− PDAC (68%; reference). Conclusions: Survival after upfront resection of anatomically resectable PDAC is worse in patients with CA19-9 ≥ 500 U/mL, while performance status had no impact. This supports consideration of CA19-9 in preoperative staging of resectable PDAC.

Published
2024

18. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

Author

Smabers, Lidwien Paula, primary, Wensink, Emerens, additional, Verissimo, Carla S., additional, Koedoot, Esmee, additional, Pitsa, Katharina-Chara, additional, Huismans, Maarten Age, additional, Barón, Celia Higuera, additional, Doorn, Mayke, additional, Iersel, Liselot B. Valkenburg-van, additional, Cirkel, Geert Anne, additional, Brousali, Anneta, additional, Overmeer, René, additional, Koopman, Miriam, additional, Braat, Manon N., additional, de Vries, Bas Penning, additional, Elias, Sjoerd G., additional, Vries, Robert G., additional, Kranenburg, Onno, additional, Boj, Sylvia F., additional, and Roodhart, Jeanine M., additional

Published
2023
Full Text
View/download PDF

19. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis

Author

Daamen, Lois A., Groot, Vincent P., Besselink, Marc G., Bosscha, Koop, Busch, Olivier R., Cirkel, Geert A., van Dam, Ronald M., Festen, Sebastiaan, Groot Koerkamp, Bas, Haj Mohammad, Nadia, van der Harst, Erwin, de Hingh, Ignace H. J. T., Intven, Martijn P. W., Kazemier, Geert, Los, Maartje, Meijer, Gert J., de Meijer, Vincent E., Nieuwenhuijs, Vincent B., Pranger, Bobby K., Raicu, Mihaela G., Schreinemakers, Jennifer M. J., Stommel, Martijn W. J., Verdonk, Robert C., Verkooijen, Helena M., Molenaar, Izaak Quintus, and van Santvoort, Hjalmar C.

Published
2020
Full Text
View/download PDF

20. Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study

Author

Augustinus, Simone, primary, van Laarhoven, Hanneke W. M., additional, Cirkel, Geert A., additional, de Groot, Jan Willem B., additional, Groot Koerkamp, Bas, additional, Macarulla, Teresa, additional, Melisi, Davide, additional, O'Reilly, Eileen M., additional, van Santvoort, Hjalmar C., additional, Mackay, Tara M., additional, Besselink, Marc G., additional, and Wilmink, Johanna W., additional

Published
2023
Full Text
View/download PDF

21. Impact of nationwide implementation of best practices in pancreatic cancer care (PACAP-1): a stepped-wedge cluster randomised controlled trial

Author

Augustinus, Simone, primary, Mackay, Tara M., additional, Latenstein, Anouk E.J., additional, van der Geest, Lydia G., additional, Bogte, Auke, additional, Bonsing, Bert A., additional, Bos, Hendrik, additional, Bosscha, Koop, additional, Borsens, Lodewijk A.A., additional, Cirkel, Geert A., additional, Hol, Lieke, additional, Busch, Olivier R.C., additional, Creemers, Geert-Jan, additional, Curvers, Wouter L., additional, Derks, Sarah, additional, Dulk, Marcel den, additional, van Dieren, Susan, additional, van Driel, Lydi M.J.W., additional, Festen, Sebastiaan, additional, van Geenen, Erwin J.M., additional, de Groot, Derk-Jan A., additional, de Groot, Jan-Willem B., additional, Koerkamp, Bas Groot, additional, Mohammad, Nadia Haj, additional, Haberkorn, Brigitte C.M., additional, Haver, Joyce T., additional, van der Harst, Erwin, additional, Hemmink, G.J. Maarten, additional, de Hingh, Ignace H., additional, Hoge, Chantal, additional, Homs, Marjolein Y.V., additional, Inderson, Akin, additional, Jacobs, Maarten A.J.M., additional, Kerver, Emile D., additional, Liem, Mike S.L., additional, Los, Maartje, additional, Lubbinge, Hans, additional, Luelmo, Saskia A.C., additional, de Meijer, Vincent E., additional, Mekenkamp, Leonie, additional, Molenaar, I. Quintus, additional, Patijn, Gijs A., additional, Quispel, Rutger, additional, Römkens, Tessa E.H., additional, van Santvoort, Hjalmar C., additional, Schreinemakers, Jennifer M.J., additional, Schut, Heidi, additional, Seerden, Tom, additional, Stommel, Martijn W.J., additional, Venneman, Niels G., additional, Verdonk, Robert C., additional, Verheij, Joanne, additional, van Vilsteren, Frederike G.I., additional, de Vos-Geelen, Judith, additional, Vulink, Annelie, additional, Wientjes, Caroline A., additional, Wit, Fennie, additional, Wessels, Frank J., additional, Zonderhuis, Babs, additional, Henri van Werkhoven, C., additional, van Hooft, Jeanin E., additional, van Eijck, Casper H.J., additional, Wilmink, Johanna W., additional, van Laarhoven, Hanneke W.M., additional, and Besselink, Marc G., additional

Published
2023
Full Text
View/download PDF

22. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial.

Author

Mackay, Tara M., Latenstein, Anouk E. J., Augustinus, Simone, van der Geest, Lydia G., Bogte, Auke, Bonsing, Bert A., Cirkel, Geert A., Hol, Lieke, Busch, Olivier R., den Dulk, Marcel, van Driel, Lydi M. J.W., Festen, Sebastiaan, de Groot, Derk-Jan A., de Groot, Jan-Willem B., Groot Koerkamp, Bas, Haj Mohammad, Nadia, Haver, Joyce T., van der Harst, Erwin, de Hingh, Ignace H., and Homs, Marjolein Y. V.

Published
2024
Full Text
View/download PDF

24. Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

Author

Geurts, Birgit S., Battaglia, Thomas W., van Berge Henegouwen, J. Maxime, Zeverijn, Laurien J., de Wit, Gijs F., Hoes, Louisa R., van der Wijngaart, Hanneke, van der Noort, Vincent, Roepman, Paul, de Leng, Wendy W.J., Jansen, Anne M.L., Opdam, Frans L., de Jonge, Maja J.A., Cirkel, Geert A., Labots, Mariette, Hoeben, Ann, Kerver, Emile D., Bins, Adriaan D., Erdkamp, Frans G.L., van Rooijen, Johan M., Houtsma, Danny, Hendriks, Mathijs P., de Groot, Jan Willem B., Verheul, Henk M.W., Gelderblom, Hans, Voest, Emile E., Geurts, Birgit S., Battaglia, Thomas W., van Berge Henegouwen, J. Maxime, Zeverijn, Laurien J., de Wit, Gijs F., Hoes, Louisa R., van der Wijngaart, Hanneke, van der Noort, Vincent, Roepman, Paul, de Leng, Wendy W.J., Jansen, Anne M.L., Opdam, Frans L., de Jonge, Maja J.A., Cirkel, Geert A., Labots, Mariette, Hoeben, Ann, Kerver, Emile D., Bins, Adriaan D., Erdkamp, Frans G.L., van Rooijen, Johan M., Houtsma, Danny, Hendriks, Mathijs P., de Groot, Jan Willem B., Verheul, Henk M.W., Gelderblom, Hans, and Voest, Emile E.

Published
2023

25. Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN):a protocol of a multicenter prospective patient preference non-randomized trial

Author

Augustinus, Simone, Broekman, Thijmen, Creemers, Geert Jan, Daamen, Lois A., van Dieren, Susan, de Groot, Jan Willem B., Cirkel, Geert A., Homs, Marjolein Y.V., van Laarhoven, Hanneke W.M., van Leeuwen, Lobke, Los, Maartje, Luelmo, Saskia A.C., van Oijen, Martijn G.H., Spierings, Leontine E.A.M., de Vos-Geelen, Judith, Besselink, Marc G., Wilmink, Johanna W., Augustinus, Simone, Broekman, Thijmen, Creemers, Geert Jan, Daamen, Lois A., van Dieren, Susan, de Groot, Jan Willem B., Cirkel, Geert A., Homs, Marjolein Y.V., van Laarhoven, Hanneke W.M., van Leeuwen, Lobke, Los, Maartje, Luelmo, Saskia A.C., van Oijen, Martijn G.H., Spierings, Leontine E.A.M., de Vos-Geelen, Judith, Besselink, Marc G., and Wilmink, Johanna W.

Published
2023

26. Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer:An International Expert Survey and Case-Vignette Study

Author

Augustinus, Simone, van Laarhoven, Hanneke W.M., Cirkel, Geert A., de Groot, Jan Willem B., Groot Koerkamp, Bas, Macarulla, Teresa, Melisi, Davide, O’Reilly, Eileen M., van Santvoort, Hjalmar C., Mackay, Tara M., Besselink, Marc G., Wilmink, Johanna W., Augustinus, Simone, van Laarhoven, Hanneke W.M., Cirkel, Geert A., de Groot, Jan Willem B., Groot Koerkamp, Bas, Macarulla, Teresa, Melisi, Davide, O’Reilly, Eileen M., van Santvoort, Hjalmar C., Mackay, Tara M., Besselink, Marc G., and Wilmink, Johanna W.

Abstract

Background: The use of imaging, in general, and during follow-up after resection of pancreatic cancer, is increasing. Consequently, the number of asymptomatic patients diagnosed with metastatic pancreatic cancer (mPDAC) is increasing. In these patients, palliative systemic therapy is the only tumor-directed treatment option; hence, it is often immediately initiated. However, delaying therapy in asymptomatic palliative patients may preserve quality of life and avoid therapy-related toxicity, but the impact on survival is unknown. This study aimed to gain insight into the current perspectives and clinical decision=making of experts regarding the timing of treatment initiation of patients with asymptomatic mPDAC. Methods: An online survey (13 questions, 9 case-vignettes) was sent to all first and last authors of published clinical trials on mPDAC over the past 10 years and medical oncologists of the Dutch Pancreatic Cancer Group. Inter-rater variability was determined using the Kappa Light test. Differences in the preferred timing of treatment initiation among countries, continents, and years of experience were analyzed using Fisher’s exact test.Results: Overall, 78 of 291 (27%) medical oncologists from 15 countries responded (62% from Europe, 23% from North America, and 15% from Asia–Pacific). The majority of respondents (63%) preferred the immediate initiation of chemotherapy following diagnosis. In 3/9 case-vignettes, delayed treatment was favored in specific clinical contexts (i.e., patient with only one small lung metastasis, significant comorbidities, and higher age). A significant degree of inter-rater variability was present within 7/9 case-vignettes. The recommended timing of treatment initiation differed between continents for 2/9 case-vignettes (22%), in 7/9 (77.9%) comparing the Netherlands with other countries, and based on years of experience for 5/9 (56%). Conclusions: Althou

Published
2023

28. Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

Author

Palliatieve Zorg, Pathologie Pathologen staf, Cancer, Pathologie Moleculair, MS Medische Oncologie, Externen Med. Onco, Geurts, Birgit S, Battaglia, Thomas W, van Berge Henegouwen, J Maxime, Zeverijn, Laurien J, de Wit, Gijs F, Hoes, Louisa R, van der Wijngaart, Hanneke, van der Noort, Vincent, Roepman, Paul, de Leng, Wendy W J, Jansen, Anne M L, Opdam, Frans L, de Jonge, Maja J A, Cirkel, Geert A, Labots, Mariette, Hoeben, Ann, Kerver, Emile D, Bins, Adriaan D, Erdkamp, Frans G L, van Rooijen, Johan M, Houtsma, Danny, Hendriks, Mathijs P, de Groot, Jan-Willem B, Verheul, Henk M W, Gelderblom, Hans, Voest, Emile E, Palliatieve Zorg, Pathologie Pathologen staf, Cancer, Pathologie Moleculair, MS Medische Oncologie, Externen Med. Onco, Geurts, Birgit S, Battaglia, Thomas W, van Berge Henegouwen, J Maxime, Zeverijn, Laurien J, de Wit, Gijs F, Hoes, Louisa R, van der Wijngaart, Hanneke, van der Noort, Vincent, Roepman, Paul, de Leng, Wendy W J, Jansen, Anne M L, Opdam, Frans L, de Jonge, Maja J A, Cirkel, Geert A, Labots, Mariette, Hoeben, Ann, Kerver, Emile D, Bins, Adriaan D, Erdkamp, Frans G L, van Rooijen, Johan M, Houtsma, Danny, Hendriks, Mathijs P, de Groot, Jan-Willem B, Verheul, Henk M W, Gelderblom, Hans, and Voest, Emile E

Published
2023

29. Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protocol of a multicenter prospective patient preference non-randomized trial.

Author

Augustinus, Simone, Broekman, Thijmen, Creemers, Geert-Jan, Daamen, Lois A., van Dieren, Susan, de Groot, Jan-Willem B., Cirkel, Geert A., Homs, Marjolein Y. V., van Laarhoven, Hanneke W. M., van Leeuwen, Lobke, Los, Maartje, Luelmo, Saskia A. C., van Oijen, Martijn G. H., Spierings, Leontine E. A. M., de Vos-Geelen, Judith, Besselink, Marc G., and Wilmink, Johanna W.

Subjects
PANCREATIC tumors, RESEARCH, METASTASIS, MANN Whitney U Test, REGRESSION analysis, T-test (Statistics), QUESTIONNAIRES, CHI-squared test, DESCRIPTIVE statistics, KAPLAN-Meier estimator, QUALITY of life, LONGITUDINAL method, OVERALL survival, PROPORTIONAL hazards models
Abstract

The article focuses on a multicenter prospective patient preference trial named "Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN)." Topics include the lack of evidence on treatment initiation timing, the potential benefits and risks of immediate versus delayed systemic treatment, and the trial's methodology, including patient eligibility criteria and study design alteration due to recruitment challenges.

Published
2023
Full Text
View/download PDF

30. Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

Author

Geurts, Birgit S., primary, Battaglia, Thomas W., additional, van Berge Henegouwen, J. Maxime, additional, Zeverijn, Laurien J., additional, de Wit, Gijs F., additional, Hoes, Louisa R., additional, van der Wijngaart, Hanneke, additional, van der Noort, Vincent, additional, Roepman, Paul, additional, de Leng, Wendy W. J., additional, Jansen, Anne M. L., additional, Opdam, Frans L., additional, de Jonge, Maja J. A., additional, Cirkel, Geert A., additional, Labots, Mariette, additional, Hoeben, Ann, additional, Kerver, Emile D., additional, Bins, Adriaan D., additional, Erdkamp, Frans G.L., additional, van Rooijen, Johan M., additional, Houtsma, Danny, additional, Hendriks, Mathijs P., additional, de Groot, Jan-Willem B., additional, Verheul, Henk M. W., additional, Gelderblom, Hans, additional, and Voest, Emile E., additional

Published
2023
Full Text
View/download PDF

31. Additional file 2 of Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

Author

Geurts, Birgit S., Battaglia, Thomas W., van Berge Henegouwen, J. Maxime, Zeverijn, Laurien J., de Wit, Gijs F., Hoes, Louisa R., van der Wijngaart, Hanneke, van der Noort, Vincent, Roepman, Paul, de Leng, Wendy W. J., Jansen, Anne M. L., Opdam, Frans L., de Jonge, Maja J. A., Cirkel, Geert A., Labots, Mariette, Hoeben, Ann, Kerver, Emile D., Bins, Adriaan D., Erdkamp, Frans G.L., van Rooijen, Johan M., Houtsma, Danny, Hendriks, Mathijs P., de Groot, Jan-Willem B., Verheul, Henk M. W., Gelderblom, Hans, and Voest, Emile E.

Abstract

Additional file 2.

Published
2023
Full Text
View/download PDF

32. A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies

Author

Cirkel, Geert A., Kerklaan, Bojana Milojkovic, Vanhoutte, Frédéric, der Aa, Annegret Van, Lorenzon, Giocondo, Namour, Florence, Pujuguet, Philippe, Darquenne, Sophie, de Vos, Filip Y. F., Snijders, Tom J., Voest, Emile E., Schellens, Jan H. M., and Lolkema, Martijn P.

Published
2016
Full Text
View/download PDF

33. Abstract 4112: Patient derived organoids predict clinical response: A patient in the lab

Author

Verissimo, Carla S., primary, Smabers, Lidwien, additional, Wensink, Emerens, additional, Koedoot, Esmee, additional, Huismans, Maarten, additional, Barón, Celia Higuera, additional, Korporaal, Ricardo, additional, Teal, Emma, additional, Pitsa, Katerina-Chara, additional, van Oosten, Edwin, additional, Nair, Roshni, additional, Valkenburg, Liselot, additional, Cirkel, Geert, additional, Brousali, Anneta, additional, Salij, Jorieke, additional, Overmeer, René, additional, Braat, Manon, additional, Elias, Sjoerd, additional, Vries, Robert, additional, Kranenburg, Onno, additional, Koopman, Miriam, additional, Boj, Sylvia F., additional, and Roodhart, Jeanine, additional

Published
2022
Full Text
View/download PDF

34. Timing of onset of systemic treatment in asymptomatic patients with metastatic pancreatic cancer: An international expert survey and case-vignette study.

Author

Augustinus, Simone, primary, Van Laarhoven, Hanneke W.M., additional, Cirkel, Geert A., additional, de Groot, Jan Willem, additional, Groot Koerkamp, Bas, additional, Macarulla, Teresa, additional, Melisi, Davide, additional, O'Reilly, Eileen Mary, additional, van Santvoort, Hjalmar, additional, Mackay, Tara, additional, Besselink, Marc G, additional, and Wilmink, Johanna, additional

Published
2022
Full Text
View/download PDF

35. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands A Nationwide Analysis

Author

Daamen, Lois A., Groot, Vincent P., Besselink, Marc G., Bosscha, Koop, Busch, Olivier R., Cirkel, Geert A., Meijer, G.J., Stommel, M.W.J., Molenaar, Izaak Quintus, Santvoort, Hjalmar C. van, Daamen, Lois A., Groot, Vincent P., Besselink, Marc G., Bosscha, Koop, Busch, Olivier R., Cirkel, Geert A., Meijer, G.J., Stommel, M.W.J., Molenaar, Izaak Quintus, and Santvoort, Hjalmar C. van

Abstract

Item does not contain fulltext

Published
2022

36. Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer:A Nationwide Study

Author

Pijnappel, Esther N., Schuurman, Melinda, Wagner, Anna D., de Vos-Geelen, Judith, Geest, Lydia G.M.van der, de Groot, Jan Willem B., Koerkamp, Bas Groot, de Hingh, Ignace H.J.T., Homs, Marjolein Y.V., Creemers, Geert Jan, Cirkel, Geert A., van Santvoort, Hjalmar C., Busch, Olivier R., Besselink, Marc G., van Eijck, Casper H.J., Wilmink, Johanna W., van Laarhoven, Hanneke W.M., Pijnappel, Esther N., Schuurman, Melinda, Wagner, Anna D., de Vos-Geelen, Judith, Geest, Lydia G.M.van der, de Groot, Jan Willem B., Koerkamp, Bas Groot, de Hingh, Ignace H.J.T., Homs, Marjolein Y.V., Creemers, Geert Jan, Cirkel, Geert A., van Santvoort, Hjalmar C., Busch, Olivier R., Besselink, Marc G., van Eijck, Casper H.J., Wilmink, Johanna W., and van Laarhoven, Hanneke W.M.

Abstract

BackgroundBiological sex, gender and age have an impact on the incidence and outcome in patients with metastatic pancreatic cancer. The aim of this study is to investigate whether biological sex, gender and age are associated with treatment allocation and overall survival (OS) of patients with metastatic pancreatic cancer in a nationwide cohort. MethodsPatients with synchronous metastatic pancreatic cancer diagnosed between 2015 and 2019 were selected from the Netherlands Cancer Registry (NCR). The association between biological sex and the probability of receiving systemic treatment were examined with multivariable logistic regression analyses. Kaplan Meier analyses with log-rank test were used to describe OS. ResultsA total of 7470 patients with metastatic pancreatic cancer were included in this study. Fourty-eight percent of patients were women. Women received less often systemic treatment (26% vs. 28%, P=0.03), as compared to men. Multivariable logistic regression analyses with adjustment for confounders showed that women <= 55 years of age, received more often systemic treatment (OR 1.82, 95% CI 1.24-2.68) compared to men of the same age group. In contrast, women at >55 years of age had a comparable probability to receive systemic treatment compared to men of the same age groups. After adjustment for confounders, women had longer OS compared to men (HR 0.89, 95% CI 0.84-0.93). ConclusionThis study found that women in general had a lower probability of receiving systemic treatment compared to men, but this can mainly be explained by age differences. Women had better OS compared to men after adjustment for confounders.

Published
2022

37. Short- and Long-Term Outcomes of Pancreatic Cancer Resection in Elderly Patients:A Nationwide Analysis

Author

Henry, Anne Claire, Schouten, Thijs J., Daamen, Lois A., Walma, Marieke S., Noordzij, Peter, Cirkel, Geert A., Los, Maartje, Besselink, Marc G., Busch, Olivier R., Bonsing, Bert A., Bosscha, Koop, van Dam, Ronald M., Festen, Sebastiaan, Groot Koerkamp, Bas, van der Harst, Erwin, de Hingh, Ignace H.J.T., Kazemier, Geert, Liem, Mike S., de Meijer, Vincent E., Nieuwenhuijs, Vincent B., Roos, Daphne, Schreinemakers, Jennifer M.J., Stommel, Martijn W.J., Molenaar, I. Quintus, van Santvoort, Hjalmar C., Henry, Anne Claire, Schouten, Thijs J., Daamen, Lois A., Walma, Marieke S., Noordzij, Peter, Cirkel, Geert A., Los, Maartje, Besselink, Marc G., Busch, Olivier R., Bonsing, Bert A., Bosscha, Koop, van Dam, Ronald M., Festen, Sebastiaan, Groot Koerkamp, Bas, van der Harst, Erwin, de Hingh, Ignace H.J.T., Kazemier, Geert, Liem, Mike S., de Meijer, Vincent E., Nieuwenhuijs, Vincent B., Roos, Daphne, Schreinemakers, Jennifer M.J., Stommel, Martijn W.J., Molenaar, I. Quintus, and van Santvoort, Hjalmar C.

Abstract

Background The number of elderly patients with pancreatic cancer is growing, however clinical data on the short-term outcomes, rate of adjuvant chemotherapy, and survival in these patients are limited and we therefore performed a nationwide analysis. Methods Data from the prospective Dutch Pancreatic Cancer Audit were analyzed, including all patients undergoing pancreatic cancer resection between January 2014 and December 2016. Patients were classified into two age groups: <75 and >= 75 years. Major complications (Clavien-Dindo grade 3 or higher), 90-day mortality, rates of adjuvant chemotherapy, and survival were compared between age groups. Factors associated with start of adjuvant chemotherapy and survival were evaluated with logistic regression and multivariable Cox regression analysis. Results Of 836 patients, 198 were aged >= 75 years (24%) and 638 were aged <75 years (76%). Median follow-up was 38 months (interquartile range [IQR] 31-47). Major complications (31% vs. 28%; p = 0.43) and 90-day mortality (8% vs. 5%; p = 0.18) did not differ. Adjuvant chemotherapy was started in 37% of patients aged >= 75 years versus 69% of patients aged <75 years (p < 0.001). Median overall survival (OS) was 15 months (95% confidence interval [CI] 14-18) versus 21 months (95% CI 19-24; p < 0.001). Age >= 75 years was not independently associated with OS (hazard ratio 0.96, 95% CI 0.79-1.17; p = 0.71), but was associated with a lower rate of adjuvant chemotherapy (odds ratio 0.27, 95% CI 0.18-0.40; p < 0.001). Conclusions The rate of major complications and 90-day mortality after pancreatic resection did not differ between elderly and younger patients; however, elderly patients were less often treated with adjuvant chemotherapy and their OS was shorter.

Published
2022

38. Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study

Author

Pijnappel, Esther N., primary, Schuurman, Melinda, additional, Wagner, Anna D., additional, de Vos-Geelen, Judith, additional, Geest, Lydia G. M. van der, additional, de Groot, Jan-Willem B., additional, Koerkamp, Bas Groot, additional, de Hingh, Ignace H. J. T., additional, Homs, Marjolein Y. V., additional, Creemers, Geert-Jan, additional, Cirkel, Geert A., additional, van Santvoort, Hjalmar C., additional, Busch, Olivier R., additional, Besselink, Marc G., additional, van Eijck, Casper H.J., additional, Wilmink, Johanna W., additional, and van Laarhoven, Hanneke W. M., additional

Published
2022
Full Text
View/download PDF

40. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): Study protocol for a trial within a cohort study

Author

Schraa, S. J., Van Rooijen, K. L., Van Der Kruijssen, D. E.W., Rubio Alarcón, C., Phallen, J., Sausen, M., Simmons, J., Coupé, V. M.H., Van Grevenstein, W. M.U., Elias, S., Verkooijen, H. M., Laclé, M. M., Bosch, L. J.W., Van Den Broek, D., Meijer, G. A., Velculescu, V. E., Fijneman, R. J.A., Vink, G. R., Koopman, M., Dunker, Mich S., Lutke Holzik, Martijn F., Hoekstra, Ronald, Sommeijer, Dirkje W., Van Der Bilt, Jarmila D.W., Consten, Esther C.J., Cirkel, Geert A., Burghgraef, Thijs A., Van Der Schans, Emma M., Nieboer, Peter, Rietbroek, Ron C., Dekker, Jan Willem T., Verschoor, Arjan J., Talsma, Koen A.K., Brosens, Rebecca P.M., Helgason, Helgi H., Marinelli, Andreas W.K.S., De Hingh, Ignace H.J.T., Oldenhuis, Corina N., Jansen, Jan, Van Halteren, Henk K., Stockmann, Hein B.A.C., Beeker, Aart, Bosscha, Koop, Pruijt, Hans F.M., Spierings, Leontine E.A.M.M., Valkenburg-Van Iersel, Liselot B.J., Vles, Wouter J., De Jongh, Felix E., Van Cruijsen, Hester, Heikens, Joost T., Zimmerman, David D.E., Van Alphen, Robert J., Schiphorst, Anandi H.W., Van Leeuwen-Snoeks, Lobke L., Vogelaar, Jeroen F.J., Peters, Natascha A.J.B., Epidemiology and Data Science, APH - Methodology, CCA - Cancer Treatment and quality of life, Pathology, Internal medicine, Orthopedic Surgery and Sports Medicine, VU University medical center, Surgery, ​Robotics and image-guided minimally-invasive surgery (ROBOTICS), RS: NUTRIM - R3 - Respiratory & Age-related Health, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Medische Oncologie (9), Medical Biology, Nephrology, and Oncology

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, Neoplasm, Residual, Colorectal cancer, Cost-Benefit Analysis, COLORECTAL-CANCER, Circulating Tumor DNA, Study Protocol, 0302 clinical medicine, RESIDUAL DISEASE, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Prospective Studies, Colectomy, Netherlands, Randomized Controlled Trials as Topic, RISK, education.field_of_study, RANDOMIZED CONTROLLED-TRIAL, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Colon cancer, Oxaliplatin, Chemotherapy, Adjuvant, CELL-FREE DNA, 030220 oncology & carcinogenesis, Colonic Neoplasms, Practice Guidelines as Topic, SURVIVAL, Female, medicine.drug, Cohort study, Adult, medicine.medical_specialty, Population, TwiCs, lcsh:RC254-282, Disease-Free Survival, LEUCOVORIN, Capecitabine, 03 medical and health sciences, Internal medicine, Genetics, medicine, Biomarkers, Tumor, Humans, RECURRENCE, education, Neoplasm Staging, Intention-to-treat analysis, business.industry, Liquid Biopsy, ctDNA, Patient Acceptance of Health Care, medicine.disease, Minimal residual disease, FLUOROURACIL, Adjuvant chemotherapy, 030104 developmental biology, Quality of Life, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

Background Accurate detection of patients with minimal residual disease (MRD) after surgery for stage II colon cancer (CC) remains an urgent unmet clinical need to improve selection of patients who might benefit form adjuvant chemotherapy (ACT). Presence of circulating tumor DNA (ctDNA) is indicative for MRD and has high predictive value for recurrent disease. The MEDOCC-CrEATE trial investigates how many stage II CC patients with detectable ctDNA after surgery will accept ACT and whether ACT reduces the risk of recurrence in these patients. Methods/design MEDOCC-CrEATE follows the ‘trial within cohorts’ (TwiCs) design. Patients with colorectal cancer (CRC) are included in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) and give informed consent for collection of clinical data, tissue and blood samples, and consent for future randomization. MEDOCC-CrEATE is a subcohort within PLCRC consisting of 1320 stage II CC patients without indication for ACT according to current guidelines, who are randomized 1:1 into an experimental and a control arm. In the experimental arm, post-surgery blood samples and tissue are analyzed for tissue-informed detection of plasma ctDNA, using the PGDx elio™ platform. Patients with detectable ctDNA will be offered ACT consisting of 8 cycles of capecitabine plus oxaliplatin while patients without detectable ctDNA and patients in the control group will standard follow-up according to guideline. The primary endpoint is the proportion of patients receiving ACT when ctDNA is detectable after resection. The main secondary outcome is 2-year recurrence rate (RR), but also includes 5-year RR, disease free survival, overall survival, time to recurrence, quality of life and cost-effectiveness. Data will be analyzed by intention to treat. Discussion The MEDOCC-CrEATE trial will provide insight into the willingness of stage II CC patients to be treated with ACT guided by ctDNA biomarker testing and whether ACT will prevent recurrences in a high-risk population. Use of the TwiCs design provides the opportunity to randomize patients before ctDNA measurement, avoiding ethical dilemmas of ctDNA status disclosure in the control group. Trial registration Netherlands Trial Register: NL6281/NTR6455. Registered 18 May 2017, https://www.trialregister.nl/trial/6281

Published
2020
Full Text
View/download PDF

41. Author Correction: Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features (Nature Communications, (2021), 12, 1, (574), 10.1038/s41467-020-20887-6)

Author

CMM Groep Cuppen, Cancer, Mendelaar, Pauline A.J., Smid, Marcel, van Riet, Job, Angus, Lindsay, Labots, Mariette, Steeghs, Neeltje, Hendriks, Mathijs P., Cirkel, Geert A., van Rooijen, Johan M., Ten Tije, Albert J., Lolkema, Martijn P., Cuppen, Edwin, Sleijfer, Stefan, Martens, John W.M., Wilting, Saskia M., CMM Groep Cuppen, Cancer, Mendelaar, Pauline A.J., Smid, Marcel, van Riet, Job, Angus, Lindsay, Labots, Mariette, Steeghs, Neeltje, Hendriks, Mathijs P., Cirkel, Geert A., van Rooijen, Johan M., Ten Tije, Albert J., Lolkema, Martijn P., Cuppen, Edwin, Sleijfer, Stefan, Martens, John W.M., and Wilting, Saskia M.

Published
2021

42. Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer

Author

MS Medische Oncologie, Cancer, Guman, Noori A M, van Geffen, Roos J, Mulder, Frits I, van Haaps, Thijs F, Hovsepjan, Vahram, Labots, Mariette, Cirkel, Geert A, de Vos, Filip Y F L, Ten Tije, Albert J, Beerepoot, Laurens V, Tjan-Heijnen, Vivianne C G, van Laarhoven, Hanneke W M, Hamberg, Paul, Vulink, Annelie J E, Los, Maartje, Zwinderman, Aeilko H, Ferwerda, Bart, Lolkema, Martijn P J K, Steeghs, Neeltje, Büller, Harry R, Kamphuisen, Pieter W, van Es, Nick, MS Medische Oncologie, Cancer, Guman, Noori A M, van Geffen, Roos J, Mulder, Frits I, van Haaps, Thijs F, Hovsepjan, Vahram, Labots, Mariette, Cirkel, Geert A, de Vos, Filip Y F L, Ten Tije, Albert J, Beerepoot, Laurens V, Tjan-Heijnen, Vivianne C G, van Laarhoven, Hanneke W M, Hamberg, Paul, Vulink, Annelie J E, Los, Maartje, Zwinderman, Aeilko H, Ferwerda, Bart, Lolkema, Martijn P J K, Steeghs, Neeltje, Büller, Harry R, Kamphuisen, Pieter W, and van Es, Nick

Published
2021

43. Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features

Author

CMM Groep Cuppen, Externen Med. Onco, MS Medische Oncologie, Cancer, CMM, Mendelaar, Pauline A J, Smid, Marcel, van Riet, Job, Angus, Lindsay, Labots, Mariette, Steeghs, Neeltje, Hendriks, Mathijs P, Cirkel, Geert A, van Rooijen, Johan M, Ten Tije, Albert J, Lolkema, Martijn P, Cuppen, Edwin, Sleijfer, Stefan, Martens, John W M, Wilting, Saskia M, CMM Groep Cuppen, Externen Med. Onco, MS Medische Oncologie, Cancer, CMM, Mendelaar, Pauline A J, Smid, Marcel, van Riet, Job, Angus, Lindsay, Labots, Mariette, Steeghs, Neeltje, Hendriks, Mathijs P, Cirkel, Geert A, van Rooijen, Johan M, Ten Tije, Albert J, Lolkema, Martijn P, Cuppen, Edwin, Sleijfer, Stefan, Martens, John W M, and Wilting, Saskia M

Published
2021

46. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands

Author

Daamen, Lois A., Groot, Vincent P., Besselink, Marc G., Bosscha, Koop, Busch, Olivier R., Cirkel, Geert A., van Dam, Ronald M., Festen, Sebastiaan, Groot Koerkamp, Bas, Haj Mohammad, Nadia, van der Harst, Erwin, de Hingh, Ignace H. J. T., Intven, Martijn P. W., Kazemier, Geert, Los, Maartje, Meijer, Gert J., de Meijer, Vincent E., Nieuwenhuijs, Vincent B., Pranger, Bobby K., Raicu, Mihaela G., Schreinemakers, Jennifer M. J., Stommel, Martijn W. J., Verdonk, Robert C., Verkooijen, Helena M., Molenaar, Izaak Quintus, and van Santvoort, Hjalmar C.

Published
2022
Full Text
View/download PDF

47. Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study

Author

Weeber, Fleur, Cirkel, Geert A, Hoogstraat, Marlous, Bins, Sander, Gadellaa-van Hooijdonk, Christa G M, Ooft, Salo, van Werkhoven, Erik, Willems, Stefan M, van Stralen, Marijn, Veldhuis, Wouter B, Besselink, Nicolle J M, Horlings, Hugo M, Steeghs, Neeltje, de Jonge, Maja J, Langenberg, Marlies H G, Wessels, Lodewyk F A, Cuppen, Edwin P J G, Schellens, J H, Sleijfer, Stefan, Lolkema, Martijn P., Voest, Emile E, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, and Medical Oncology

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Pediatrics, 03 medical and health sciences, 0302 clinical medicine, predict response, Internal medicine, Journal Article, medicine, PTEN, Tumor biopsy, In patient, PI3K/AKT/mTOR pathway, Everolimus, Copy number loss, biology, business.industry, biomarkers, clinical study, everolimus, Exact test, 030104 developmental biology, time to progression ratio, 030220 oncology & carcinogenesis, biology.protein, Biomarker (medicine), Clinical Research Paper, business, medicine.drug
Abstract

Background: In this study, our aim was to identify molecular aberrations predictive for response to everolimus, an mTOR inhibitor, regardless of tumor type. Methods: To generate hypotheses about potential markers for sensitivity to mTOR inhibition, drug sensitivity and genomic profiles of 835 cell lines were analyzed. Subsequently, a multicenter study was conducted. Patients with advanced solid tumors lacking standard of care treatment options were included and underwent a pre-treatment tumor biopsy to enable DNA sequencing of 1,977 genes, derive copy number profiles and determine activation status of pS6 and pERK. Treatment benefit was determined according to TTP ratio and RECIST. We tested for associations between treatment benefit and single molecular aberrations, clusters of aberrations and pathway perturbation. Results: Cell line screens indicated several genes, such as PTEN (P = 0.016; Wald test), to be associated with sensitivity to mTOR inhibition. Subsequently 73 patients were included, of which 59 started treatment with everolimus. Response and molecular data were available from 43 patients. PTEN aberrations, i.e. copy number loss or mutation, were associated with treatment benefit (P = 0.046; Fisher's exact test). Conclusion: Loss-of-function aberrations in PTEN potentially represent a tumor type agnostic biomarker for benefit from everolimus and warrants further confirmation in subsequent studies.

Published
2017

48. Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids

Author

Divisie Beeld & Oncologie, Cancer, Externen Med. Onco, Unit Opleiding Aios, Genetica Lab. Metabole Diagnostiek, MS Medische Oncologie, van der Velden, Daphne L., Cirkel, Geert A., Houthuijzen, Julia M., van Werkhoven, E., Roodhart, Jeanine M.L., Daenen, Laura G.M., Kaing, Sovann, Gerrits, Johan, Verhoeven-Duif, Nanda M., Grootscholten, Cecile, Boot, Henk, Sessa, Cristisiana, Bloemendal, Haiko J., de Vos, Filip Y., Voest, Emile E., Divisie Beeld & Oncologie, Cancer, Externen Med. Onco, Unit Opleiding Aios, Genetica Lab. Metabole Diagnostiek, MS Medische Oncologie, van der Velden, Daphne L., Cirkel, Geert A., Houthuijzen, Julia M., van Werkhoven, E., Roodhart, Jeanine M.L., Daenen, Laura G.M., Kaing, Sovann, Gerrits, Johan, Verhoeven-Duif, Nanda M., Grootscholten, Cecile, Boot, Henk, Sessa, Cristisiana, Bloemendal, Haiko J., de Vos, Filip Y., and Voest, Emile E.

Published
2018

49. Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Weeber, Fleur, Cirkel, Geert A, Hoogstraat, Marlous, Bins, Sander, Gadellaa-van Hooijdonk, Christa G M, Ooft, Salo, van Werkhoven, Erik, Willems, Stefan M, van Stralen, Marijn, Veldhuis, Wouter B, Besselink, Nicolle J M, Horlings, Hugo M, Steeghs, Neeltje, de Jonge, Maja J, Langenberg, Marlies H G, Wessels, Lodewyk F A, Cuppen, Edwin P J G, Schellens, J H, Sleijfer, Stefan, Lolkema, Martijn P., Voest, Emile E, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Weeber, Fleur, Cirkel, Geert A, Hoogstraat, Marlous, Bins, Sander, Gadellaa-van Hooijdonk, Christa G M, Ooft, Salo, van Werkhoven, Erik, Willems, Stefan M, van Stralen, Marijn, Veldhuis, Wouter B, Besselink, Nicolle J M, Horlings, Hugo M, Steeghs, Neeltje, de Jonge, Maja J, Langenberg, Marlies H G, Wessels, Lodewyk F A, Cuppen, Edwin P J G, Schellens, J H, Sleijfer, Stefan, Lolkema, Martijn P., and Voest, Emile E

Published
2017

50. Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study

Author

Weeber, Fleur (author), Cirkel, Geert A. (author), Hoogstraat, Marlous (author), Bins, Sander (author), Gadellaa-van Hooijdonk, Christa G.M. (author), Ooft, Salo (author), van Werkhoven, Erik (author), Willems, Stefan M. (author), van Stralen, Marijn (author), Veldhuis, Wouter B. (author), Besselink, Nicolle J.M. (author), Horlings, Hugo M. (author), Steeghs, Neeltje (author), de Jonge, Maja J. (author), Langenberg, Marlies H.G. (author), Wessels, L.F.A. (author), Cuppen, Edwin (author), Schellens, J.H. (author), Sleijfer, Stefan (author), Lolkema, Martijn P. (author), Voest, Emile E. (author), Weeber, Fleur (author), Cirkel, Geert A. (author), Hoogstraat, Marlous (author), Bins, Sander (author), Gadellaa-van Hooijdonk, Christa G.M. (author), Ooft, Salo (author), van Werkhoven, Erik (author), Willems, Stefan M. (author), van Stralen, Marijn (author), Veldhuis, Wouter B. (author), Besselink, Nicolle J.M. (author), Horlings, Hugo M. (author), Steeghs, Neeltje (author), de Jonge, Maja J. (author), Langenberg, Marlies H.G. (author), Wessels, L.F.A. (author), Cuppen, Edwin (author), Schellens, J.H. (author), Sleijfer, Stefan (author), Lolkema, Martijn P. (author), and Voest, Emile E. (author)

Abstract

Background: In this study, our aim was to identify molecular aberrations predictive for response to everolimus, an mTOR inhibitor, regardless of tumor type. Methods: To generate hypotheses about potential markers for sensitivity to mTOR inhibition, drug sensitivity and genomic profiles of 835 cell lines were analyzed. Subsequently, a multicenter study was conducted. Patients with advanced solid tumors lacking standard of care treatment options were included and underwent a pre-treatment tumor biopsy to enable DNA sequencing of 1,977 genes, derive copy number profiles and determine activation status of pS6 and pERK. Treatment benefit was determined according to TTP ratio and RECIST. We tested for associations between treatment benefit and single molecular aberrations, clusters of aberrations and pathway perturbation. Results: Cell line screens indicated several genes, such as PTEN (P = 0.016; Wald test), to be associated with sensitivity to mTOR inhibition. Subsequently 73 patients were included, of which 59 started treatment with everolimus. Response and molecular data were available from 43 patients. PTEN aberrations, i.e. copy number loss or mutation, were associated with treatment benefit (P = 0.046; Fisher's exact test). Conclusion: Loss-of-function aberrations in PTEN potentially represent a tumor type agnostic biomarker for benefit from everolimus and warrants further confirmation in subsequent studies., Pattern Recognition and Bioinformatics

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results